Ojas Shah, MD
Dr. Ojas Shah, George F. Cahill Professor of Urology and Director of Endourology and Stone Disease, is a member of Columbia University's Department of Urology. His clinical interests include surgical and metabolic treatments of kidney stone disease, minimally invasive urologic surgery, upper tract transitional cell carcinoma/urothelial carcinoma, ureteral strictures, ureteropelvic junction (UPJ) obstruction, ureteral/renal reconstructive surgery, and BPH (benign prostate hyperplasia).
He is a graduate of Northwestern University School of Medicine. He completed his general surgical and urologic training at New York University Medical Center. He spent an additional year at Wake Forest University Health Sciences Center as a fellow in endourology, laparoscopy and metabolic stone disease.
Dr. Shah is nationally active as a member of the American Urological Association Surgical Management of Stones Guidelines Committee. He is the director of the Endourology Fellowship Program at Columbia University. He also has a strong focus on medical student and resident education, and served as the urology residency program director at NYU and Chief of Urology of Bellevue Hospital in New York prior to joining Columbia.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Endourology/Stone Disease)Ineligible company:AurisMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Endourology/Stone Disease)Ineligible company:AmbiMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Endourology/Stone Disease)Ineligible company:Boston ScientificMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Endourology/Stone Disease)Ineligible company:ColoplastMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Endourology/Stone Disease)Ineligible company:Applaud MedicalMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Meeting Participant or Lecturer (Endourology/Stone Disease)Ineligible company:American Urological AssociationMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:Spouse or PartnerType of financial relationship:Investment Interest (General Urology)Ineligible company:NJ Kidney Stone CenterMitigation strategy:Peer reviewDate reviewed:07/07/2023
-
Attribution:SelfType of financial relationship:Health Publishing (General Urology)Ineligible company:ElsevierMitigation strategy:Peer reviewDate reviewed:07/07/2023